|
|
|
European Biopharmaceutical Review
|
Personalised medicine means that medical treatment can be tailored towards an individual after a disease has been – hopefully correctly – diagnosed. The treatment should take multiple factors such as age, weight, lifestyle, and, ultimately, genomic information into account. The more precisely and reliably this can be done, the better the patient should respond to the therapy without any unwanted adverse effects.
Nowadays, the term ‘personalised medicine’ is almost exclusively associated with next generation sequencing (NGS) or whole genome sequencing (WGS), respectively. This means one essentially takes a sample (a simple stick in the mouth serves this purpose well) and sends it to their favourite NGS company, which will probably cost less than €1,000, and then they get a long list of diseases and a probability that they will develop one of these diseases or they already have one or multiple diseases. However, that is not the whole story, and, probably, the more interesting story starts there.
A Brief History of WGS
At the beginning in 1990, sequencing the entire human genome for the first time took 13 years and $3 billion. Nine years later, 69 more human genomes were sequenced. In 2016, the University of Toronto launched a project to sequence 10,000 genomes within one year (1). As of the beginning of 2018, the 100,000 genomes project has reached almost 40,000 sequenced genomes and is expected to reach its goal by end of the same year (2). When you look at the cost for sequencing a genome (see Figure 1, page 54, noting the logarithmic y-scale), it becomes clear what a tremendous progress the whole technique has made over the past few years. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for pharmaceutical and medical device applications
Novo Nordisk Pharmatech A/S has entered into an agreement with Signet
Chemical Corporation Pvt. Ltd. for the distribution of their
pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to
the healthcare industry in India, Bangladesh and Sri Lanka.
More info >> |
|
 |
White Papers |
 |
|
Successfully managing the unique demands of cell therapy supply chains
PCI Pharma Services
Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >> |
|
 |
Industry Events |
 |
Drug Discovery 2018
9-10 October 2018, ExCeL Arena, London, UK
ELRIG’s flagship conference, Drug Discovery, has become the
largest meeting of life sciences industry professionals in the UK. Now in its
12th year, Drug Discovery 2018 will take place in London’s Excel Arena. This
2-day event will bring together more than 1200 delegates and over 100
exhibiting companies from around the world who will highlight the latest
ground-breaking research, discuss cutting-edge advances in the application of
laboratory technology to understand disease biology and to identify novel
chemical and biological candidate drugs.
More info >> |
|
|
